Thermo Fisher Scientific 주식 (NYSE: TMO)

에 대한 최신 뉴스 Thermo Fisher Scientific (NYSE:TMO) 주식

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).

News

Commodities

Markets

AXON

CPNG

IDXX

ISRG

MELI

PCAR

SPOT

케이티 허버티(Katy Huberty)는 모건 스탠리의 글로벌 리서치 책임자로, 인공지능(AI) 도입으로 인해 상당한 이점을 얻을 가능성이 있는 20개의 주식을 주목했다. 무슨 일이 있었나: 허버티는 현재 AI 도입을 위한 &#34;전환점&#34;에 있다고 언급했다. 그녀는 AI를 활용하여 수익을 증대시키는 기업들이 상당한 혜택을 누릴 준비가 되어 있다고 강조했다.

모건 스탠리, 인공지능 채택이 임계치에 도달함에 따라 상위 20개 AI 기반 주식 공개

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Equities

Previews

Tech

Trading Ideas

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMOE ENGINEERING CO by Tomoe Engineering Co. Ltd.

Trimol Group Inc

&quot;Trian commends Solventum on the announced sale of its Purification &amp; Filtration business and believes this is an important first step in the Company&#39;s value creation journey. We believe that part of what attracted strategic interest at such a high valuation multiple was the division&#39;s differentiated technology and material science &ndash; attributes inherited from 3M which are present at Solventum&#39;s remaining businesses, and which we believe remain underappreciated by the market today.&quot;
&nbsp;
Thermo Fisher Also Commented &quot;Excluding Financing Costs, the Transaction Is Expected to Be Accretive by $0.28 in That Period. This Reflects the Very Strong Day One Cost Synergies When Solventum&#39;s Allocated Segment Costs Are Replaced by Lower Run Rate Costs Within Thermo Fisher.&quot;
&nbsp;
&nbsp;

SOLV

Trian Fund Management Which Beneficially Owns ~5% Of Solventum Corporation Comments On Solventum's Recently Announced Sale Of Its Purification & Filtration Business To Thermo Fisher Scientific

Dan&nbsp;Loeb‘s&nbsp;Third Point LLC, which has a varied mix of stock from across the sectors, did some major portfolio restructuring in the <a target="_blank" href="https://www.benzinga.com/topic/dan-loeb" rel="noreferrer noopener">last quarter of 2024</a>.
According to recent 13F filings,&nbsp;reflecting his holding as of Dec. 31, 2024, Loeb slashed a stake in the major Life Sciences Tools &amp; Services company Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">to </a>1,900,000 from 1,950,000 shares <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624005927/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">in </a>the third quarter of 2024, a decline of around 2.5%.
Notably, the investor has been cutting stake in Danaher in the last couple of quarters. Earlier, he held 2,050,000 shares <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514624004004/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">as </a>of second quarter of 2024 and 2,450,000 shares as <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1040273/000108514623004511/xslForm13F_X02/infotable.xml" rel="noreferrer noopener">of </a>third quarter of 2023.
Instead, the investor acquired a stake in Danaher&#8217;s major peer Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), attaining 350,000 shares in the fourth quarter 2024.
Read: <a target="_blank" href="https://www.benzinga.com/25/02/43861240/repligens-q4-earnings-beat-2025-guidance-highlights-market-growth" rel="noreferrer noopener">Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook</a>
DHR Major Events:
<ul>
<li>In January, the company reported weaker-than-expected fourth-quarter earnings, with adjusted earnings per share of $2.14 missing the street view of $2.16 and sales of $6.54 billion (+2%), beating the analyst <a href="https://www.benzinga.com/news/earnings/25/01/43298036/danaher-q4-eps-miss-expectations-amid-diagnostics-segment-lag" target="_blank" rel="noreferrer noopener">consensus estimate of $6.42 billion</a>.</li>
<li>Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter. However, it anticipates a 3% year-over-year increase in <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">core revenue for the full year of 2025</a>.</li>
<li>Following the earnings release, several analysts cut the price forecast on the stock, with Barclays analyst Luke Sergott lowering the price forecast from $275 to $240 and Wells Fargo analyst Brandon Couillard curtailing the price target from $280 to $240 and <a href="https://www.benzinga.com/25/01/43336758/danaher-analysts-cut-their-forecasts-after-downbeat-earnings" target="_blank" rel="noreferrer noopener">both maintaining an Equal-Weight</a>.</li>
<li>This month, Danaher raised quarterly dividend <a href="https://www.benzinga.com//node/43866316" target="_blank" rel="noreferrer noopener">per share from&nbsp;$0.27&nbsp;to&nbsp;$0.32</a>.</li>
</ul>
TMO Major Events:
<ul>
<li>Last month, the company reported fourth-quarter adjusted earnings per share of $6.10, beating the street view of $5.94 and sales of $11.395 billion (+5% year over year) outpaced the analyst <a href="https://www.benzinga.com/25/01/43337781/thermo-fisher-q4-earnings-beat-estimates-margin-expands" target="_blank" rel="noreferrer noopener">consensus estimate of $11.277 billion</a>.</li>
<li>Following the earnings release, several analysts raised the price forecast on the stock, with Morgan Stanley analyst Tejas Savant increasing the price target from&nbsp;$647&nbsp;to&nbsp;$678 and Wells Fargo analyst Brandon Couillard upped <a href="https://www.benzinga.com/quote/TMO/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from&nbsp;$660&nbsp;to&nbsp;$680</a>.</li>
<li>This month, Thermo Fisher Scientific raised its quarterly dividend<a href="https://www.benzinga.com//node/43830343" target="_blank" rel="noreferrer noopener"> from $0.39 to $0.43 per share</a>.</li>
<li>Thermo Fisher inked a 10-year VPPA with X-ELIO to enhance renewable energy access in pharmaceutical and healthcare supply chains through the Lorca solar project, set to launch <a href="https://www.benzinga.com/pressreleases/25/02/b43460138/thermo-fisher-scientific-accelerates-100-percent-renewable-electricity-goal-for-european-operation" target="_blank" rel="noreferrer noopener">in early 2026 with three industry partners</a>.</li>
</ul>
Year to date, Danaher shares declined around 10% while Thermo Fisher rose 0.66%, both underperforming the iShares U.S. Healthcare ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), which gained about 5%&nbsp;over the same time frame.
Also, the companies top peers Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) fell roughly 0.3% and IQVIA Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) declined about 1.3% so far this year.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43796723/dan-loebs-third-point-boosts-meta-holdings-now-a-top-4-position" target="_blank" rel="noreferrer noopener">Dan Loeb&#8217;s Third Point Boosts Meta Holdings, Now A Top 4 Position</a></li>
</ul>
Photo: Shutterstock

Large Cap

ETFs

iShares Trust Dow Jones US Healthcare Sector Index Fund

Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor

On Tuesday, Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) agreed to acquire Solventum&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) Purification &amp; Filtration business for approximately $4.1 billion in cash.
Solventum&#8217;s Purification &amp; Filtration business provides purification and filtration technologies for the production of biologics, medical technologies and industrial applications.
The Solventum business operates globally, with sites in the Americas, Europe, the Middle East, Africa and the Asia-Pacific region. The company has approximately 2,500 employees.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43337781/thermo-fisher-q4-earnings-beat-estimates-margin-expands" rel="noreferrer noopener">Thermo Fisher Q4 Earnings Beat Estimates, Margin Expands</a>
In 2024, Solventum&#8217;s Purification &amp; Filtration business generated approximately $1 billion in revenue.
Solventum&#8217;s Purification &amp; Filtration business complements Thermo Fisher&#8217;s bioproduction business.
&#8220;The addition of Solventum&#8217;s business is an outstanding strategic fit with our company and will create significant value for our customers and shareholders,&#8221; said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher.
The transaction is expected to be completed by the end of 2025.
The Purification &amp; Filtration business will become part of Thermo Fisher&#8217;s Life Sciences Solutions segment and is expected to generate mid-to-high-single-digit organic growth. The application of the PPI Business System will enable strong margin expansion and meaningful synergy realization.
The transaction is expected to be dilutive to adjusted EPS&nbsp;by $0.06 in the first year of ownership.
Excluding financing costs, the transaction is expected to be accretive by $0.28 in that period.
Thermo Fisher expects to realize approximately $125 million of adjusted operating income from revenue and cost synergies by year five following the close.
Price Action: TMO stock closed at $535.55 on Monday. SOLV stock is up 1.93% at $77.75 during the premarket session on last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43938612/eli-lilly-expands-zepbound-vial-options-lowers-prices-for-25-mg-5-mg-doses" target="_blank" rel="noreferrer noopener">Eli Lilly Expands Zepbound Vial Options, Lowers Prices For 2.5 mg, 5 Mg Doses</a></li>
</ul>
Photo: Shutterstock

Health Care

General

Thermo Fisher Bets Big On Bioproduction With Solventum's Unit Deal Worth $4.1 Billion

Thermo Fisher To Acquire Solventum's Purification And Filtration Business For $4.1B In Cash

<a href="https://www.wsj.com/business/deals/thermo-fisher-nears-deal-for-solventum-filtration-unit-e0bb5519?mod=Searchresults_pos2&amp;page=1" title="https://www.wsj.com/business/deals/thermo-fisher-nears-deal-for-solventum-filtration-unit-e0bb5519?mod=Searchresults_pos2&amp;page=1">https://www.wsj.com/business/deals/thermo-fisher-nears-deal-for-solventum-filtration-unit-e0bb5519?mod=Searchresults_pos2&amp;page=1</a>

Wall Street Journal Reported Monday, Thermo Fisher Scientific Nears Deal For Solventum's Purification And Filtration Business; Deal Could Be Announced This Week

Investors with a lot of money to spend have taken a bullish stance on Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TMO, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Thermo Fisher Scientific.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 12%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $317,353, and there was 1 call, for a total amount of $35,057.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $610.0 for Thermo Fisher Scientific over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Thermo Fisher Scientific options trades today is 223.5 with a total volume of 322.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Thermo Fisher Scientific's big money trades within a strike price range of $500.0 to $610.0 over the last 30 days.
<h3>Thermo Fisher Scientific Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740168995_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$24.5</td>
<td>$22.8</td>
<td>$24.5</td>
<td>$560.00</td>
<td>$66.1K</td>
<td align="right">504</td>
<td align="right">17</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$25.8</td>
<td>$23.1</td>
<td>$24.6</td>
<td>$560.00</td>
<td>$51.6K</td>
<td align="right">504</td>
<td align="right">83</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$43.3</td>
<td>$38.9</td>
<td>$40.61</td>
<td>$530.00</td>
<td>$44.6K</td>
<td align="right">2</td>
<td align="right">11</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$25.8</td>
<td>$23.1</td>
<td>$24.6</td>
<td>$560.00</td>
<td>$44.2K</td>
<td align="right">504</td>
<td align="right">101</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$13.1</td>
<td>$12.3</td>
<td>$12.3</td>
<td>$500.00</td>
<td>$40.5K</td>
<td align="right">388</td>
<td align="right">37</td>
</tr>
</tbody>
</table>

<h3>About Thermo Fisher Scientific</h3>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
<h3>Present Market Standing of Thermo Fisher Scientific</h3>
<ul>
<li>With a trading volume of 788,069, the price of TMO is down by -0.81%, reaching $533.5.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 61 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Thermo Fisher Scientific</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $672.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Thermo Fisher Scientific, which currently sits at a price target of $715. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Thermo Fisher Scientific, targeting a price of $650. 
&#x2A; An analyst from Raymond James downgraded its action to Outperform with a price target of $667. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on Thermo Fisher Scientific with a target price of $680. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Thermo Fisher Scientific, which currently sits at a price target of $650. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Thermo Fisher Scientific options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Thermo Fisher Scientific Unusual Options Activity

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 13.19% since its last report. The company recently reported that it has 3.95 million shares sold short, which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.92 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740084326_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 5.56%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?utm_source=insights&amp;adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Thermo Fisher Scientific's Recent Short Interest

CNBC Final Trades: XOM, LNG, TMO

Dividends

Thermo Fisher Scientific Increases Quarterly Dividend From $0.39 To $0.43

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 15 years by 5.16% on an annualized basis producing an average annual return of 17.2%. Currently, Thermo Fisher Scientific has a market capitalization of $200.16 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 15 years ago, it would be worth $1,053.53 today based on a price of $523.29 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739910608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 15 Years

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 5.75% on an annualized basis producing an average annual return of 16.83%. Currently, Thermo Fisher Scientific has a market capitalization of $226.56 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 10 years ago, it would be worth $4,800.04 today based on a price of $592.33 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738595709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Scotiabank analyst Sung Ji Nam maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform and raises the price target from $605 to $650.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on Thermo Fisher Scientific, Raises Price Target to $650

Raymond James analyst Andrew Cooper reiterates Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and raises the price target from $650 to $667.

Reiteration

Raymond James Reiterates Outperform on Thermo Fisher Scientific, Raises Price Target to $667

Citigroup analyst Patrick Donnelly maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Neutral and raises the price target from $600 to $650.

Citigroup Maintains Neutral on Thermo Fisher Scientific, Raises Price Target to $650

UBS analyst Dan Leonard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and raises the price target from $700 to $715.

UBS Maintains Buy on Thermo Fisher Scientific, Raises Price Target to $715

Throughout the last three months, 5 analysts have evaluated Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $654.0, with a high estimate of $680.00 and a low estimate of $605.00. Experiencing a 1.36% decline, the current average is now lower than the previous average price target of $663.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738350029_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Thermo Fisher Scientific's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$680.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$678.00</td>
<td>$647.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$647.00</td>
<td>$670.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$605.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$660.00</td>
<td>$675.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Thermo Fisher Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Thermo Fisher Scientific compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Thermo Fisher Scientific's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Thermo Fisher Scientific's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TMO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Thermo Fisher Scientific analyst ratings.</a>
<h2>Discovering Thermo Fisher Scientific: A Closer Look</h2>
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
<h3>Thermo Fisher Scientific: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Thermo Fisher Scientific's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.23% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Thermo Fisher Scientific's net margin is impressive, surpassing industry averages. With a net margin of 15.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Thermo Fisher Scientific's ROE excels beyond industry benchmarks, reaching 3.38%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Thermo Fisher Scientific's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.64% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Thermo Fisher Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.72.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Thermo Fisher Scientific's Future

Wells Fargo analyst Brandon Couillard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and raises the price target from $660 to $680.

Wells Fargo Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $680

Morgan Stanley analyst Tejas Savant maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Overweight and raises the price target from $647 to $678.

Morgan Stanley Maintains Overweight on Thermo Fisher Scientific, Raises Price Target to $678

WIIM

Thermo Fisher Scientific shares are trading higher after the company reported better-than-expected Q4 financial results.

Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) shares are trading higher in <a href="https://www.benzinga.com/pressreleases/25/01/b43330138/thermo-fisher-scientific-reports-fourth-quarter-and-full-year-2024-results" target="_blank" rel="noreferrer noopener">Thursday&#8217;s premarket session.</a>
The company reported fourth-quarter adjusted earnings per share of $6.10, beating the street view of $5.94. Quarterly sales of $11.395 billion (+5% year over year) outpaced the analyst consensus estimate of $11.277 billion.
&#8220;We drove meaningful share gain and enabled the success of our customers, by leveraging our proven growth strategy and PPI Business System, capping off another year of differentiated performance,&#8221; said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific.
Organic revenue growth was 4% and Core organic revenue growth was 5%.
Also Read:<a target="_blank" href="https://www.benzinga.com/25/01/43325888/tesla-likely-to-sell-optimus-to-rival-companies-in-2026-price-point-of-humanoid-robot-to-be-detemined-by-demand-says-ceo-elon-musk" rel="noreferrer noopener"> Tesla Likely To Sell Optimus To Rivals In 2026, Elon Musk Says Revenue Potential Of Bot North Of $10 Trillion: &#8216;It&#8217;s Real Bananas&#8217;</a>
Thermo Fisher&#8217;s operating income in the quarter under review increased to $2.016 billion, higher than $1.854 billion in the year-ago period.
Operating margin expanded to 17.7% from 17% in the year-ago period.
The company exited the quarter with cash and equivalents worth $4.009 billion, and inventories worth $4.978 billion.
&#8220;We are in a great position to deliver excellent performance in 2025 as we continue to create value for all of our stakeholders and build an even brighter future for our company,&#8221; Casper added.
Thermo Fisher&#8217;s long-term obligations as of quarter-end are pegged at $29.061 billion.
Revenue for the full year was $42.88 billion in 2024 versus $42.86 billion in 2023. Organic revenue and Core organic revenue growth were flat.
Price Action: TMO shares are trading higher by 3.9% to $590.42 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43259304/trumps-proposed-corporate-tax-cuts-could-boost-teslas-fy25-eps-by-4-says-analyst" target="_blank" rel="noreferrer noopener">Trump's Proposed Corporate Tax Cuts Could Boost Tesla's FY25 EPS by 4%, Says Analyst</a></li>
</ul>
Photo: Shutterstock

Earnings

Thermo Fisher Q4 Earnings Beat Estimates, Margin Expands

Press Releases

Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Study

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2024 Results

Thermo Fisher Scientific Accelerates 100 Percent Renewable Electricity Goal for European Operations with New Solar Power Agreement with X-ELIO

GeminiBio Appoints Mike Stella to Board

Thermo Fisher Scientific Elects New Director to Board

Thermo Fisher Scientific Increases Quarterly Dividend

Thermo Fisher Scientific to Present at TD Cowen 45th Annual Health Care Conference on March 3, 2025

Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

Trian Comments on Solventum's Sale of its Purification & Filtration Business

AMGN

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Fortrea Holdings

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Scotiabank

Raymond James

Citigroup

Wells Fargo

Screenshot 2024-12-19 at 7.13.05 PM

Biotech

MYNZ

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

케이티 허버티(Katy Huberty)는 모건 스탠리의 글로벌 리서치 책임자로, 인공지능(AI) 도입으로 인해 상당한 이점을 얻을 가능성이 있는 20개의 주식을 주목했다.
무슨 일이 있었나: 허버티는 현재 AI 도입을 위한 &#8220;전환점&#8221;에 있다고 언급했다. 그녀는 AI를 활용하여 수익을 증대시키는 기업들이 상당한 혜택을 누릴 준비가 되어 있다고 강조했다.
허버티는 이번 달 초 <a href="https://www.businessinsider.com/ai-adopters-stocks-to-buy-beneficiaries-pricing-power-morgan-stanley-2025-1#home-depot-1">비즈니스 인사이더</a>와의 인터뷰에서 강력한 가격 결정력을 가진 기업, 즉 높은 수요로 인해 가격을 유지하거나 인상할 수 있는 기업들이 가장 큰 수익성 향상을 경험할 것이라고 지적했다.
그녀는 &#8220;가격 결정력은 기업들이 이러한 투자로 인한 생산성 향상을 고객에게 전가하지 않고 유지할 수 있게 해 줄 것&#8221;이라고 설명했다.
또한, 허버티는 그녀의 팀이 고객 노트에서 작성한 주식 목록을 언급했다. 이 주식들은 모두 AI를 도입하고 높은 가격 결정력을 가진 기업들로, 시가총액이 200억 달러 이상이다. 목록에는 홈디포(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>), 써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), 인튜이티브 서지컬(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), 디어 앤 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), 스포티파이 테크놀로지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), 메르카도리브레(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), 메리어트 인터내셔널(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), 힐튼 월드와이드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>), 파카(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>), 슐럼버거 NV(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>), 존슨 컨트롤스 인터내셔널 PLC(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>), 엑슨 엔터프라이즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>), 쿠팡(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>), 베이커 휴즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), 익스피리언 PLC, 델타 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), 아이덱스 래버러토리스(NASDAQ:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), 유나이티드 에어라인 홀딩스(NASDAQ:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/UA#NASDAQ">UA</a>) 및 할리버튼(NYSE:<a class="ticker" style="font-size: revert;" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) 등이 포함되어 있다.
왜 중요한가요: AI 도입은 최근 몇 년간 뜨거운 주제가 되었으며, 많은 산업에서 비즈니스 운영을 혁신하고 수익성을 높일 수 있는 잠재력을 인식하고 있다.
허버티가 이러한 20개 주식을 지적한 것은 비즈니스 환경에서 AI의 중요성이 커지고 있음을 강조한다. AI 기술을 성공적으로 활용하는 기업들은 경쟁 우위를 얻을 수 있으며, 특히 강력한 가격 결정력을 가진 기업들이 그렇다.
이러한 발전은 투자 전략의 변화를 시사할 수 있으며, 투자자들이 강력한 AI 도입을 가진 기업들을 유망한 투자 기회로 보게 될 가능성이 있다.
다음 읽을거리:
<a href="https://www.benzinga.com/markets/25/01/43217038/aoc-says-democrats-in-congress-are-doing-insider-trading-people-think-that-everyday-people-are-stupid">AOC, &#8220;의회 민주당원들이 내부자 거래를 하고 있다&#8221;: &#8216;사람들은 일반 사람들이 바보라고 생각한다&#8217;</a>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>QXO(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>)의 주가는 <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">사모 금융 유치</a>를 발표한 이후 33.37% 상승했다.</li>
<li>아반토(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>)의 주식은 S&amp;P MidCap 400에 편입된다는 발표 이후 지난 주에 21.62% 상승했다. 또한 예상보다 나은 2분기 실적을 발표했다.</li>
<li>유니버셜 헬스 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>)는 회사가 예상보다 나은 2분기 실적을 발표하고 <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">2024 회계연도 지침을</a> 상향 조정한 후 주가가 17.73% 상승했다.</li>
<li>맨하탄 어소시에이츠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고한 후 17.02% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)의 주가는 <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">예상보다 좋은 2분기 실적</a>에 힘입어 15.53% 상승했다.</li>
<li>퍼스트 시티즌스 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>)의 주가는 회사의 분기 실적이 예상보다 높았음을 보고한 후 15.15% 상승했다.</li>
<li>테넷 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>)는 예상보다 나은 2분기 재무 결과를 보고한 후 주가가 13.02% 상승했으며, 회사는 FY24 지침을 추정치보다 높이고 3분기 지침을 추정치보다 높게 발표했다. 또한 회사는 <a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">15억 달러 규모의</a> 자사주 매입을 승인했다고 발표했다.</li>
<li>CBRE 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>)은 회사가 2024년 목표를 상향 조정한 후 지난 주 주가가 12.99% 상승했다. 몇몇 분석가들은 주식에 대한 가격 <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">예측</a>을 높였다.</li>
<li>써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 주가는 지난주 12.63% 상승했다. 이 회사는 연간 전망을 <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.</li>
<li>다나허(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)의 주가는 회사가 예상보다 나은 2분기 실적을 보고한 후 11.30% 상승하여 더 높게 거래되고 있다.</li>
<li>록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)의 주가는 긍정적인 애널리스트 <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">평가와 강한 2분기 실적</a>에 힘입어 10.72% 상승했다.</li>
</ol>
다음 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ed%8f%ac%eb%93%9c-%ec%8a%a4%ed%85%94%eb%9e%80%ed%8b%b0%ec%8a%a4-%eb%b0%8f-%eb%8d%b8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-12/" target="_blank" rel="noopener">포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일~7월 27일)</a></li>
</ul>
썸네일 제공: 셔터스톡
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

S&amp;P 500 기업들 중 약 <a href="https://www.benzinga.com/news/earnings/24/07/39769910/goldman-sachs-q2-earnings-revenue-and-eps-beat-investment-banking-fees-up-21-hikes-dividend" target="_blank" rel="noopener" data-google-interstitial="false">14%가 6월 분기 실적을 발표</a>했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.
지난주 주요 사건: 기술주의 실적 시즌은 지난주 칩 장비 제조업체 ASML 홀딩 N.V.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)의 실적 발표로 와만하게 시작되었다. 이 회사의 주가는 약한 3분기 전망과 중국 칩 금지를 둘러싼 지정학적 우려로 인해 약 16% 하락했다. 넷플릭스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>)의 지침은 투자자들을 실망시켰지만 증권사 측 분석가들이 결과에 열광하면서 주가는 크게 하락하지 않았다.
투자자들은 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), 모건 스탠리(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) 및 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) 등 나머지 대형 은행들의 실적 보고서에 환호했다. 투자 은행 사업의 반등과 강력한 트레이딩 매출이 은행들의 매출을 강화하는 데 도움이 되었다.
팩트셋(FactSet)의 최신 실적 전망 조사 <a href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_071924.pdf">보고서</a>에 따르면 이들 기업 중 80%가 예상보다 높은 주당 이익을 보고했는데, 이는 5년 평균인 77%와 비교된다. 평균 상승 여력은 약 5.5%이지만, 이는 5년 평균 상승률 8.6%보다 낮다.
관련 정보: <a href="https://www.benzinga.com/money/best-tech-stocks">지금 가장 핫한 기술주</a>
실적 트렌드: 팩트셋에 따르면 S&amp;P 500 기업들의 2분기 혼합 실적 증가율은 현재 9.7%로 전주의 9.1%보다 높아진 것으로 추정된다. 이 추정치가 달성되면 분기 실제 성장률은 2021년 4분기 이후 보고된 전년 동기 대비 가장 높은 성장률을 기록할 것이라고 덧붙였다. 2분기 역시 4분기 연속 성장을 기록할 것으로 보인다.
S&amp;P 500 11개 부문 중 8개 부문이 전년 동기 대비 실적 성장을 기록할 것으로 예상되며, 그 중 통신 서비스, 의료, IT, 금융 부문 4개 부문이 두 자릿수 실적 성장을 기록할 가능성이 높다. 반면, 소재 업종을 중심으로 3개 업종의 실적 감소가 예상된다.
이번 주의 이슈: 이번 주에는 다우 30 지수 구성요소 7개를 포함해 S&amp;P 500 기업 138개 기업들의 실적 보고서가 나올 것이라고 팩트셋의 보고서가 밝혔다. 이번 주의 실적 발표 목록에는 통신, 자동차, 철강, 칩, 주택 건설, 방위, 항공 및 기술 산업의 기업들이 포함된다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)와 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)은 S&amp;P 500과 나스닥 지수에서 높은 비중을 차지하고 있어 주목받는 기업들 중 하나이다. 테슬라는 전년 동기 대비 주당 순이익이 91센트에서 62센트로 급격히 감소할 것으로 예상되는 반면, 매출은 훨씬 완만하게 0.80% 감소한 247억 3천만 달러를 기록했을 수 있다. 이 이익성에 더 큰 영향을 미치는 것은 일론 머스크의 회사가 어려운 수요 환경에서 생산량을 늘리기 위해 의존해 온 가격 인하에서 비롯된다.
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39810457/as-tesla-stock-bounces-back-fund-manager-says-elon-musk-led-company-offers-good-set">분석가들과 펀드 매니저들은</a> 회사가 해당 분기에 양호한 납품 실적을 보고한 후 낙관적이다. 하반기에도 반전이 있을 것으로 예상된다.
알파벳의 실적은 AI를 활용한 거대 기업들 중 최초로 분기별 실적을 발표하는 기업이기 때문에 중요하며, 이는 나머지 기업들의 실적 속도를 정할 수 있다.
지난주 주요 지수가 사상 최고치에서 후퇴하면서 주식시장이 큰 타격을 입었다. Benzinga Pro 데이터에 따르면 나스닥 100 지수의 성과를 추적하는 지수인 Invesco QQQ Trust(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)는 금요일 0.89% 하락한 475.24달러에 마감했다. 이 ETF는 7월 10일에 도달한 502.96달러의 사상 최고치보다 낮게 거래되고 있다. SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)도 금요일 0.66% 하락한 548.99달러로 마감했다.
이번 주 주목할 만한 실적 발표 기업은 다음과 같다:
월요일
개장 전:
<ul>
<li>버라이즌 커뮤니케이션스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</li>
</ul>
장 마감 후:
<ul>
<li>애질리시스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>)</li>
<li>클리블랜드 클리프스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)</li>
<li>뉴코 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>)</li>
<li>NXP 반도체 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>)</li>
</ul>
화요일
개장 전:
<ul>
<li>코카콜라 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>)</li>
<li>프리포트 맥모란 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>)</li>
<li>GATX 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GATX#NYSE">GATX</a>)</li>
<li>GE 에어로스페이스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>)</li>
<li>제너럴 모터스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>)</li>
<li>킴벌리 클라크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>)</li>
<li>록히드 마틴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>)</li>
<li>필립 모리스 인터내셔널 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</li>
<li>풀트그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>)</li>
<li>퀘스트 다이아그노스틱스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>)</li>
<li>스포티파이 테크놀로지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>)</li>
<li>UPS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</li>
</ul>
장 마감 후:
<ul>
<li>알파벳</li>
<li>캐피털 원 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>)</li>
<li>처브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>)</li>
<li>마텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>)</li>
<li>패키징 코퍼레이션 오브 아메리카 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>)</li>
<li>씨게이트 테크놀로지 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>)</li>
<li>테슬라</li>
<li>텍사스 인스트루먼트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>)</li>
<li>비자 .(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>)</li>
</ul>
수요일
개장 전:
<ul>
<li>AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</li>
<li>체크포인트 소프트웨어 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>)</li>
<li>보스톤 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</li>
<li>CME 그룹 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>)</li>
<li>제너럴 다이내믹스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>)</li>
<li>올드 도미니언 프레이트 라인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>)</li>
<li>GE 베르노바 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)</li>
<li>써모 피셔 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)</li>
</ul>
장 마감 후:
<ul>
<li>치폴레 멕시칸 그릴 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>)</li>
<li>에드워드 라이프사이언스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>)</li>
<li>포드 자동차 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>)</li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>)</li>
<li>나이트 스위프트 트랜스포테이션 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>)</li>
<li>라스베가스 샌즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>)</li>
<li>메리티지 홈즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>)</li>
<li>월풀 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>)</li>
<li>서비스나우 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) ORLY</li>
<li>오릴리 오토모티브 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>)</li>
</ul>
목요일
개장 전:
<ul>
<li>애브비 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</li>
<li>아메리칸 항공 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>)</li>
<li>아스트라제네카 PLC(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)</li>
<li>컴캐스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)</li>
<li>다우 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>)</li>
<li>해즈브로 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>)</li>
<li>허니웰 인터내셔널 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>)</li>
<li>사노피 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)</li>
<li>사우스웨스트 항공 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>)</li>
<li>ST마이크로일렉트로닉스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>)</li>
<li>유니언 퍼시픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>)</li>
<li>제록스 홀딩스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>)</li>
</ul>
장 마감 후:
<ul>
<li>스카이웨스트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>)</li>
<li>주니퍼 네트웍스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>)</li>
<li>데커스 아웃도어 코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>)</li>
<li>보이드 게이밍 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>)</li>
<li>BJ 레스토랑 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>)</li>
<li>베리사인 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>)</li>
</ul>
금요일
개장 전:
<ul>
<li>3M 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>)</li>
<li>반즈 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>)</li>
<li>브리스톨-마이어스 스퀴브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</li>
<li>뉴웰 브랜즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>)</li>
<li>콜게이트 파몰리브 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>)</li>
<li>차터 커뮤니케이션즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>)</li>
</ul>
차기 기사:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39857569/american-express-q2-earnings-ceo-raises-annual-profit-and-marketing-spend-outlook-after-q2-profit-b">아메리칸 익스프레스, 2분기 실적: CEO의 2분기 순이익 안정화에 대한 전망</a></li>
</ul>
Photo: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

주식은 저항선에 도달한 후 매도하는 경향이 있다. 그들은 또한 지지선에서 반등하는 경향이 있다. 이러한 역학관계는 써모 피셔 사이언티픽(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>)의 차트에서 확인할 수 있다. 이것이 바로 우리 거래팀이 이를 &#8216;오늘의 <a href="https://www.benzinga.com/topic/stock-of-the-day">주식</a>&#8216;으로 선택한 이유이다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-436704" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/15132642/1-12-1024x623.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/15132642/1-12-1024x623.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/15132642/1-12-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/15132642/1-12-768x467.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/15132642/1-12.png 1042w" alt="Thermo Fisher Scientific - Well-defined support and resistance." width="1024" height="623" /></figure>
저항선은 동일한 가격 또는 그에 가까운 가격에 매도하려는 판매자들의 대규모 그룹 또는 집중이다. 써모의 경우 약 600.00달러에 잘 정의된 저항선이 있었다.
때로는 주식이 저항선 수준에 도달하면 매도를 원하는 일부 거래자들과 투자자들이 우려하게 된다. 그들은 다른 판매자들이 시장에 들어오는 것을 느낄 수 있다. 그리고 그들은 구매자들이 가장 낮은 가격에 판매하려는 사람들에게로 갈 것이라는 것을 알고 있다.
그래서 그들은 판매하려는 가격을 낮춘다. 예를 들어, 누군가 처음에 600.00달러에 판매하고 싶었지만 가격을 599.00달러로 낮추기로 결정했을 수 있다.
다른 우려하는 매도자들도 이를 보고 매도가격을 낮추기로 결정한다. 이로 인해 서로의 가격을 낮추며 눈덩이 효과가 발생하고, 가격이 더 낮아질 수 있다.
주식이 지지선에서 반등할 때는 반대의 현상이 발생한다.
지지선은 동일하거나 가까운 가격에서 매수하려는 다수의 트레이더들과 투자자들이 모여 있는 큰 집중 지점이다. 써모의 경우 535.00달러 수준에서 명확한 <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">지지선</a>이 형성되었다.
때때로 주식이 지지선까지 떨어지면 매수하려는 트레이더들과 투자자들 중 일부가 우려를 하게 된다. 그들은 <a href="https://www.benzinga.com/insights/options/24/07/39754324/looking-at-thermo-fisher-scientifics-recent-unusual-options-activity">다른 구매자들</a>이 시장에 진입하고 있음을 감지할 수 있다. 그리고 매도자들이 가장 높은 가격을 지불하려는 매수자들에게 갈 것이라는 것을 알고 있다.
그 결과, 그들은 자신이 지불하려는 가격을 올리기로 결정한다. 예를 들어, 처음에 535.00달러에 매수하려던 사람들이 가격을 536.00달러로 올리기로 결정한다. 다른 우려하는 매수자들도 이를 보고 같은 행동을 취다.
이로 인해 입찰 경쟁과 눈덩이 효과가 발생하여 주가가 상승세로 돌아설 수 있다.
트레이더들은 주식이 저항 수준에 도달한 후 반전되거나 지지 수준으로 떨어진 후 반전되는 역학을 이해해야 한다. 이는 그들에게 낮은 위험의 거래 기회를 제공할 것이다.
지금 읽어보세요: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39776800/s-p-500-prints-new-record-highs-ahead-of-powell-speech-russell-2000-rally-continues-trump-">S&amp;P 500, 파월 연설 앞두고 최고 기록 경신, 러셀 2000 랠리가 계속되고 트럼프 주식이 급등, 월요일 시장을 이끄는 요인은?</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Thermo Fisher Scientific

뉴스

에 대한 최신 뉴스 Thermo Fisher Scientific (NYSE:TMO) 주식

월요일, 1월 27, 2025

일요일, 7월 28, 2024

일요일, 7월 21, 2024

화요일, 7월 16, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌